PDS Biotechnology

PDS Biotechnology

PDSB· Manufacturing· Fiscal year ends in December

CEO pay in FY2025Stock -52.8% in FY2025

Frank Bedu-Addo, Ph.D. is the CEO of PDS Biotechnology and was paid $828.3K in FY2025 (Dec).

Pay$100 in the stock at the end of FY21 → $29
CEO pay is from each PDS Biotechnology proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Executives3

See all
  1. 1Frank Bedu-Addo, Ph.D.FY2025
  2. 2Kirk Shepard. M.D.FY2025
  3. 3Stephan ToutainFY2025

Named executives and their total pay, from the Summary Compensation Table of the latest proxy.

Pay

See all

PDS Biotechnology paid its 3 named executives $2.2M in total in FY2025 (Dec). CEO Frank Bedu-Addo, Ph.D. was paid $828.3K of that.

Name
Frank Bedu-Addo, Ph.D.Chief Executive OfficerNot disclosed
Kirk Shepard. M.D.Chief Medical Officer
Stephan ToutainChief Operating Officer

of each named executive, from the Summary Compensation Table of each proxy.

Peers

No disclosed peer group

No proxy on file names a pay peer group for PDS Biotechnology. The peer group comes from the proxy statement, so it shows here when a proxy read has it.

Board2

See all
  • Ilian IlievDirector · 5 yr on the boardNot independent—Paid as an executive
  • Otis BrawleyDirector · 5 yr on the boardIndependent—Paid as an executive

The board of the latest proxy (FY2025).

Activity

Filings6

See all
Proxy statementDEF 14AJun 26, 2026FY2025
Annual report10-KMar 30, 2026FY2025
Proxy statementDEF 14AApr 29, 2025FY2024
Annual report10-KMar 27, 2025FY2024
Proxy statementDEF 14AApr 29, 2024FY2023
Annual report10-KMar 28, 2024FY2023
For the press:Download CSVDownload PNGHow to use our data